CTOs on the Move

Ventus Therapeutics

www.ventustx.com

 
Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ventustx.com
  • 7150 Frederick-Banting
    Montreal, QC CAN H9S2A1
  • Phone: 514.397.9517

Executives

Name Title Contact Details

Funding

Ventus Therapeutics raised $60M on 05/06/2020
Ventus Therapeutics raised $100M on 04/08/2021

Similar Companies

Theranos

Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.

Synchem

Synchem is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eyenovia

Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.

Artisan Orthotic Prosthetic Technologies

Artisan Orthotic Prosthetic Technologies is a Tualatin, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mersana

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.